Among 125 HIV/HCV-coinfected people taking
antiretrovirals in a Denver group, 70% could have moderate or severe
interactions with one of four common direct-acting antiviral (DAA)
regimens for HCV . Researchers calculated that 20% of patients who
needed to switch antiretrovirals because of certain DAA interactions
could not switch because of antiretroviral resistance.
This retrospective study involved 125 HIV/HCV-coinfected adults with
antiretrovirals prescribed within the last year. All participants were
in care at an academic medical center in Denver. Researchers assessed
potential interactions between each person's antiretroviral regimen and
four possible DAA combinations: simeprevir and sofosbuvir (SIM/SOF),
sofosbuvir and ledipasvir (SOF/LDV), sofosbuvir and daclatasvir
(SOF/DCV), and ritonavir-boosted paritaprevir plus dasabuvir and
ombitasvir (3D). The analysis did not explore potential interactions
between non-HIV drugs and DAAs.
Labels: Coinfection, DDA-ARV interactions